This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

This Advisory is an update to the SMA10-4591, Vol. 9 Issue 2, published in 2010. The advisory summarizes key elements of Traumatic Brain Injury (TBI), and describes its relevance to behavioral health, including recommendations for behavioral health professionals.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This report provides findings from a qualitative analysis of evidence-based and culturally relevant behavioral health practices offered at NNEDLearn, a SAMHSA training, offered from 2011 to 2020. It includes an overview of NNEDLearn, case studies, strategies and lessons learned, and conclusion.

This guide reviews ways that telehealth modalities can be used to provide treatment for serious mental illness and substance use disorders among adults, distills the research into recommendations for practice, and provides examples of how these recommendations can be implemented.

This guide provides mental health decision-makers (e.g., state/local mental health directors, treatment facility clinical directors, and other stakeholders) with rationale and evidence to support wide-spread expansion of Cognitive Behavioral Therapy for Psychosis (CBTp) across mental health systems.

This Advisory, TIP 47, Substance Abuse: Clinical Issues in Intensive Outpatient Treatment, provides an overview of intensive outpatient (IOP) treatment. It discusses typical program goals; outlines key features that improve engagement, retention, and outcomes; and provides additional resources on this critical topic.